Showing 12 posts of 12 posts found.

Grünenthal receives FDA Breakthrough Therapy Designation for knee osteoarthritis drug

May 23, 2023
Medical Communications Breakthrough Therapy Designation, FDA, Grunenthal, Musculo-skeletal disorder, osteoarthritis

German pharmaceutical company Grünenthal has announced that the US Food and Drug Administration (FDA) has awarded it Breakthrough Therapy Designation …


Top Ten most popular articles on Pharmafile.com this week

February 22, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease

Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …


“Game-changing” osteoarthritis drug receives £675k funding from Innovate UK

February 19, 2019
Manufacturing and Production, Research and Development AKL Research and Development, Innovate UK, osteoarthritis, pharma

A novel and potentially “game-changing” oral therapy for the treatment of osteoarthritis (OA) has received a £675,000 cash injection from …


Pfizer & Lilly’s non-opioid drug reduces pain in osteoarthritis

October 24, 2018
Research and Development Eli Lilly, Pfizer, osteoarthritis, pharma

Pfizer and Eli Lilly have announced data revealing that their nerve growth factor (NGF) inhibitor tanezumab met all three of …


Anika’s osteoarthritis pain drug falls short at Phase 3

June 21, 2018
Research and Development Anika Therapeutics, Cingal, osteoarthritis, pharma

Anika Therapeutics has become the latest in a recent string of firms to suffer a failure in a late-stage trial, …


Kitov’s combo gets FDA approval in osteoarthritis and hypertension

June 1, 2018
Medical Communications, Sales and Marketing Consensi, FDA, Kitov, US, hypertension, osteoarthritis, pharma

Israeli biopharmaceutical firm is celebrating the approval in the US of Consensi, a combo of the calcium channel blocker amlodipine …


Regeneron and Teva’s experimental drug halted by FDA clinical hold

October 17, 2016
Manufacturing and Production Regeneron, Teva, back pain, osteoarthritis

Regeneron Pharmaceuticals and Teva Pharmaceuticals had only just agreed a deal worth a potential $2.6 billion to co-develop Regeneron’s fasinumab …


Teva and Regeneron team up for $2.6 billion pain treatment development

September 21, 2016
Research and Development, Sales and Marketing Regeneron, Teva, fasinumab, osteoarthritis

Teva and Regeneron have entered an agreement worth up to $2.6 billion to develop and market the latter’s experimental nerve …


Regeneron says trial drug for osteoarthritis pain meets primary endpoint in Phase II trials

May 3, 2016
Manufacturing and Production, Research and Development Phase II, Regeneron Pharmaceuticals, drug trial, osteoarthritis, phase III

Regeneron Pharmaceuticals (Nasdaq: REGN) said mid-stage trials for its drug candidate to treat osteoarthritis pain med its primary endpoint. The …


Flexion Therapeutics announce results for Zilretta trials in osteoarthritis pain

April 5, 2016
Manufacturing and Production, Research and Development drugs, flexion, flexion therapeutics, osteoarthritis, pipeline, treatments, zilretta

Flexion Therapeutics has presented positive results from two pivotal clinical trials for its lead drug candidate, Zilretta, which show that …

GSK launches global joint pain education programme

September 13, 2010
Medical Communications chronic pain, disease awareness campaigns, osteoarthritis

GlaxoSmithKline has launched a global education programme to help sufferers from musculoskeletal conditions such as arthritis to self-manage pain in …

Stem cell trial for osteoarthritis launched

July 13, 2010
Research and Development Arthritis Research UK, Stem cells, osteoarthritis

Stem cell therapy is to be used to treat patients with osteoarthritis in a new UK clinical trial. Medical research …

Latest content